Journal of Diagnostics Concepts & Practice >
Research progress on neurohumoral mechanism and clinical significance of vasovagal syncope
Received date: 2023-02-22
Online published: 2024-12-25
Vasovagal syncope (VVS) is the most common type of syncope in clinical practice, primarily caused by the excessive response of the autonomic nervous system to external stimuli, leading to vasodilation and bradycardia, and consequently reduced whole brain perfusion. At present, the pathophysiological mechanism of VVS remains largely unknown, with neurohumoral regulation playing a significant role in it. Sympathetic Nervous System (SNS) plays a crucial role in the occurrence of VVS by regulating heart rate, blood pressure and vascular tone, especially in blood pressure regulation, postural changes, and stress response. The Renin-Angiotensin-Aldosterone System (RAAS) maintains blood volume and blood pressure stability by regulating vasoconstriction and sodium and water retention. Nitric oxide (NO) and hydrogen sulfide (H2S) secreted by vascular endothelial cells as vasodilator factors, and Endothelin (ET) as vasoconstrictor factors, are involved in regulating vascular tone. Neurotransmitters such as 5-hydroxytryptamine (5-HT) and galanin also play a key role in the occurrence of VVS. SNS and RAAS are involved in the occurrence of VVS. When the hemodynamics is still in a stable state, the plasma Epi and NE concentrations increase, and the Epi increment is much higher than NE, resulting in an increase in Epi/NE value. The significant β-adrenergic effect leads to peripheral vasodilation, venous blood flow accumulation, and progressive blood pressure decline, which is the most important pathophysiological mechanism leading to syncope. When hypotension occurs, the body compensatively secretes a large amount of AVP, and the significant increase of AVP concentration further leads to vasodilation, aggravates the decrease of blood pressure, and causes syncope. In the future, more accurate VVS drug development will become the focus. Using modern pharmacology and molecular biology techniques, drugs targeting specific neurohumoral mechanisms will be developed to achieve higher efficacy with fewer side effects. Additionally, the identification and validation of new biomarkers will drive advancements in early diagnosis and monitoring of treatment outcomes.
LI Qiheng , XIE Yucai . Research progress on neurohumoral mechanism and clinical significance of vasovagal syncope[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(06) : 628 -633 . DOI: 10.16150/j.1671-2870.2024.06.011
| [1] | MORRIS J. Emergency department management of syncope[J]. Emerg Med Pract, 2021, 23(6):1-24. |
| [2] | GOLDBERGER Z D, PETEK B J, BRIGNOLE M, et al. ACC/AHA/HRS Versus ESC Guidelines for the Diagnosis and Management of Syncope: JACC Guideline Comparison[J]. J Am Coll Cardiol, 2019, 74(19):2410-2423. |
| [3] | BRIGNOLE M, MOYA A, DE LANGE F J, et al. 2018 ESC Guidelines for the diagnosis and management of syncope[J]. Eur Heart J, 2018, 39(21):1883-1948. |
| [4] | KENNY R A, INGRAM A, BAYLISS J, et al. Head-up tilt: a useful test for investigating unexplained syncope[J]. Lancet, 1986, 1(8494):1352-1355. |
| [5] | ALMQUIST A, GOLDENBERG I F, MILSTEIN S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope[J]. N Engl J Med, 1989, 320(6):346-351. |
| [6] | SHALEV Y, GAL R, TCHOU P J, et al. Echocardiographic demonstration of decreased left ventricular dimensions and vigorous myocardial contraction during syncope induced by head-up tilt[J]. J Am Coll Cardiol, 1991, 18(3):746-751. |
| [7] | FITZPATRICK A P, BANNER N, CHENG A, et al. Vasovagal reactions may occur after orthotopic heart transplantation[J]. J Am Coll Cardiol, 1993, 21(5):1132-1137. |
| [8] | HADJI-TURDEGHAL K, ANDREASEN L, HAGEN C M, et al. Genome-wide association study identifies locus at chromosome 2q32.1 associated with syncope and collapse[J]. Cardiovasc Res, 2020, 116(1):138-148. |
| [9] | RAHMOUNI K. Energy metabolism and syncope[J]. Clin Auton Res, 2022, 32(6):391-393. |
| [10] | BENDITT D G, ERMIS C, PADANILAM B, et al. Catecholamine response during haemodynamically stable upright posture in individuals with and without tilt-table induced vasovagal syncope[J]. Europace, 2003, 5(1):65-70. |
| [11] | SRA J S, MURTHY V, NATALE A, et al. Circulatory and catecholamine changes during head-up tilt testing in neurocardiogenic (vasovagal) syncope[J]. Am J Cardiol, 1994, 73(1):33-37. |
| [12] | KOHNO R, DETLOFF B L S, CHEN L Y, et al. Greater early epinephrine rise with head-up posture: A marker of increased syncope susceptibility in vasovagal fainters[J]. J Cardiovasc Electrophysiol, 2019, 30(3):289-296. |
| [13] | ERMIS C, SAMNIAH N, LURIE K G, et al. Adrenal/renal contribution to circulating norepinephrine in posturally induced neurally mediated reflex syncope[J]. Am J Cardiol, 2003, 91(6):746-750. |
| [14] | ERMIS C, SAMNIAH N, SAKAGUCHI S, et al. Comparison of catecholamine response during tilt-table-induced vasovagal syncope in patients <35 to those >65 years of age[J]. Am J Cardiol, 2004, 93(2):225-227. |
| [15] | TITOV B, MATVEEVA N, KULAKOVA O, et al. Vasovagal Syncope Is Associated with Variants in Genes Involved in Neurohumoral Signaling Pathways[J]. Genes (Basel), 2022, 13(9):1653. |
| [16] | SHELDON R, FARIS P, TANG A, et al. Midodrine for the Prevention of Vasovagal Syncope : A Randomized Clinical Trial[J]. Ann Intern Med, 2021, 174(10):1349-1356. |
| [17] | BAGRUL D, ECE I, YILMAZ A, et al. Midodrine treatment in children with recurrent vasovagal syncope[J]. Cardiol Young, 2021, 31(5):817-821. |
| [18] | GOLDSTEIN D S, HOLMES C, FRANK S M, et al. Sympathoadrenal imbalance before neurocardiogenic syncope[J]. Am J Cardiol, 2003, 91(1):53-58. |
| [19] | BENDITT D G, VAN DIJK J G, KRISHNAPPA D, et al. Neurohormones in the Pathophysiology of Vasovagal Syncope in Adults[J]. Front Cardiovasc Med, 2020, 7:76. |
| [20] | VANDERHEYDEN M, GOETHALS M, NELLENS P, et al. Different humoral responses during head-up tilt testing among patients with neurocardiogenic syncope[J]. Am Heart J, 1998, 135(1):67-73. |
| [21] | JARDINE D L, MELTON I C, CROZIER I G, et al. Neurohormonal response to head-up tilt and its role in vasovagal syncope[J]. Am J Cardiol, 1997, 79(9):1302-1306. |
| [22] | GAJEK J, ZY?KO D, MAZUREK W. Renin-angiotensin-aldosterone system activity during head-up tilt testing in patients with vasovagal syncope[J]. Pol Merkur Lekarski, 2005, 19(110):136-168. |
| [23] | MITRO P, MUDRáKOVá K, MICKOVá H, et al. Hemodynamic parameters and heart rate variability during a tilt test in relation to gene polymorphism of renin-angiotensin and serotonin system[J]. Pacing Clin Electrophysiol, 2008, 31(12):1571-1580. |
| [24] | TRESCHAN T A, PETERS J. The vasopressin system: physiology and clinical strategies[J]. Anesthesiology, 2006, 105(3):599-640. |
| [25] | RIEGGER G A, WAGNER A. Excessive secretion of vasopressin during vasovagal reaction[J]. Am Heart J, 1991, 121(2 Pt 1):602-603. |
| [26] | THEOPISTOU A, GATZOULIS K, ECONOMOU E, et al. Biochemical changes involved in the mechanism of vasovagal syncope[J]. Am J Cardiol, 2001, 88(4):376-381. |
| [27] | NILSSON D, SUTTON R, MELANDER O, et al. Spontaneous vs nitroglycerin-induced vasovagal reflex on head-up tilt: Are there neuroendocrine differences?[J]. Heart Rhythm, 2016, 13(8):1674-1678. |
| [28] | LINDENBERGER M, FEDOROWSKI A, MELANDER O, et al. Cardiovascular biomarkers and echocardiographic findings at rest and during graded hypovolemic stress in women with recurrent vasovagal syncope[J]. J Cardiovasc Electrophysiol, 2019, 30(12):2936-2943. |
| [29] | AYLWARD P E, FLORAS J S, LEIMBACH W N JR, et al. Effects of vasopressin on the circulation and its baroreflex control in healthy men[J]. Circulation, 1986, 73(6):1145-1154. |
| [30] | LI H, LIAO Y, HAN Z, et al. Head-up tilt test provokes dynamic alterations in total peripheral resistance and cardiac output in children with vasovagal syncope[J]. Acta Paediatr, 2018, 107(10):1786-1791. |
| [31] | SHI Y, TIAN H, GUI Y H, et al. Association of nitric oxide and eNOS with the pathogenesis of vasovagal syncope[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2008, 10(4):478-480. |
| [32] | ATICI A, ACIKSARI G, BAYCAN O F, et al. Serum Asymmetric Dimethylarginine Levels in Patients with Vasovagal Syncope[J]. Medicina (Kaunas), 2019, 55(11):718. |
| [33] | YANG J, LI H, OCHS T, et al. Erythrocytic hydrogen sulfide production is increased in children with vasovagal syncope[J]. J Pediatr, 2015, 166(4):965-969. |
| [34] | WANG L, CHENG C K, YI M, et al. Targeting endothelial dysfunction and inflammation[J]. J Mol Cell Cardiol, 2022, 168:58-67. |
| [35] | MAGERKURTH C, RIEDEL A, BRAUNE S. Permanent increase in endothelin serum levels in vasovagal syncope[J]. Clin Auton Res, 2005, 15(4):299-301. |
| [36] | KAUFMANN H, ORIBE E, OLIVER J A. Plasma endothelin during upright tilt: relevance for orthostatic hypotension?[J]. Lancet, 1991, 338(8782-8783):1542-1545. |
| [37] | SORRENTINO S, FORLEO C, IACOVIELLO M, et al. Endothelin system polymorphisms in tilt test-induced vasovagal syncope[J]. Clin Auton Res, 2009, 19(2):123-129. |
| [38] | HAMREFORS V, NILSSON D, MELANDER O, et al. Low Adrenomedullin and Endothelin-1 Predict Cardioinhibitory Response During Vasovagal Reflex in Adults Over 40 Years of Age[J]. Circ Arrhythm Electrophysiol, 2017, 10(10):e005585. |
| [39] | MINSON J, CHALMERS J, DROLET G, et al. Central serotonergic mechanisms in cardiovascular regulation[J]. Cardiovasc Drugs Ther, 1990, 4 Suppl 1:27-32. |
| [40] | C?Té F, FLIGNY C, FROMES Y, et al. Recent advances in understanding serotonin regulation of cardiovascular function[J]. Trends Mol Med, 2004, 10(5):232-238. |
| [41] | ALBONI P, BONDANELLI M, DINELLI M, et al. Role of the serotonergic system in the genesis of vasovagal syncope[J]. Europace, 2000, 2(2):172-180. |
| [42] | GOLDEN R N, HSIAO J K, LANE E, et al. Abnormal neuroendocrine responsivity to acute i.v. clomipramine challenge in depressed patients[J]. Psychiatry Res, 1990, 31(1):39-47. |
| [43] | THEODORAKIS G N, MARKIANOS M, LIVANIS E G, et al. Hormonal responses during tilt-table test in neurally mediated syncope[J]. Am J Cardiol, 1997, 79(12):1692-1695. |
| [44] | SHELDON R, ROSE M S, RITCHIE D, et al. Genetic Association Study in Multigenerational Kindreds With Vasovagal Syncope: Evidence for Involvement of Sex-Specific Serotonin Signaling[J]. Circ Arrhythm Electrophysiol, 2019, 12(1):e006884. |
| [45] | LANG R, GUNDLACH A L, HOLMES F E, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity[J]. Pharmacol Rev, 2015, 67(1):118-175. |
| [46] | BONDANELLI M, ALBONI P, MARGUTTI A, et al. Plasma galanin response to head-up tilt in normal subjects and patients with recurrent vasovagal syncope[J]. Metabolism, 2003, 52(3):315-321. |
| [47] | PLASEK J, DOUPAL V, FURSTOVA J, et al. The role of adrenomedullin and galanin in recurrent vasovagal syncope: a case control study[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2013, 157(2):162-167. |
| [48] | BEHNOUSH A H, YAZDANI K, KHALAJI A, et al. Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials[J]. Heart Rhythm, 2023, 20(3):448-460. |
| [49] | ABUZAINAH B, GUTLAPALLI S D, CHAUDHURI D, et al. Anxiety and Depression as Risk Factors for Vasovagal Syncope and Potential Treatment Targets: A Systematic Review[J]. Cureus, 2022, 14(12):e32793. |
/
| 〈 |
|
〉 |
